Bob Bradway, Amgen CEO (Stephen Lam/Reuters)

Am­gen launch­es the first US Hu­mi­ra biosim­i­lar at two dif­fer­ent list prices

The bizarre dy­nam­ics of the US pre­scrip­tion drug mar­ket were on full dis­play once again this morn­ing as Am­gen an­nounced that it would launch the first US biosim­i­lar for Hu­mi­ra, the best-sell­ing drug of all time, at two com­plete­ly dif­fer­ent list prices.

One price for Am­gen’s Am­je­vi­ta (adal­i­mum­ab-at­to) will be 55% be­low the cur­rent Hu­mi­ra list price, which is about $84,000 per year, and an­oth­er at a list price 5% be­low the cur­rent Hu­mi­ra list price, but pre­sum­ably (phar­ma com­pa­nies don’t dis­close re­bates) with high re­bates to at­tract PBMs and pay­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.